Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VE 303

Drug Profile

VE 303

Alternative Names: VE-303

Latest Information Update: 03 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vedanta Biosciences
  • Class Anti-infectives; Antibacterials
  • Mechanism of Action Gastrointestinal microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Clostridium difficile infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Clostridium difficile infections

Most Recent Events

  • 18 Dec 2019 Safety, pharmacokinetics and pharcodynamics data was presented in recurrent Clostridium difficile infection at the IDWeek (IDWeek-2019)
  • 20 May 2019 Expanded safety and efficacy results from a phase Ia/Ib trial in Clostridium difficile infections released by Vedanta Biosciences
  • 17 Dec 2018 Phase-II clinical trials in Clostridium difficile infections (Recurrent, Newly diagnosed) in USA (PO) (NCT03788434)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top